Biotalys Achieves Key Milestone with Syngenta in Bioinsecticide Development
Biotalys has announced reaching an initial milestone in its research partnership with Syngenta to develop an innovative bioinsecticide. Laboratory tests have shown promising in vitro results with bioactive ingredients developed using the proprietary AGROBODY™ technology.
Collaborative Efforts Towards Bioinsecticide Solutions
Biotalys and Syngenta are collaborating to develop a bioinsecticide solution aimed at combating major crop pests. The partnership is part of a joint effort to offer crop protection solutions that combine the effectiveness of conventional products with the sustainable benefits of biological solutions. Based in Ghent, Belgium, Biotalys utilizes its AGROBODY™ technology platform for this collaboration with Syngenta, a global leader in agricultural innovation.
Promising Laboratory Results
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Laboratory tests have demonstrated promising in vitro results with new bioactive ingredients developed by Biotalys targeting insecticidal molecules. The teams from both companies will proceed to the next research phase, which will involve testing the active ingredients on living organisms (in vivo tests). Syngenta will make an initial milestone payment to Biotalys, reflecting the ongoing progress of the collaboration.
Financial Impact of the Milestone Payment
The initial milestone payment from Syngenta will not materially impact the current financial autonomy of Biotalys.
Biotalys intends to maintain a cost-conscious approach to fully exploit the potential of its unique technology platform
Risks mentioned
Limited financial runway of only until end of Q1 2027 requiring additional financing
Regulatory approval delays in U.S. and E.U. for EVOCA and EVOCA NG could impact commercialisation timeline
Dependence on successful manufacturing scale-up and partnerships to achieve commercial viability of lead products
Opportunities identified
Regulatory approval pathway for EVOCA NG in U.S. (2029 launch) and Europe (2030 launch) targeting USD 1.1 billion market
BioFun-6 lead candidate demonstrating strong efficacy in field trials across multiple crops and geographies
Strategic partnership with 21st.BIO for manufacturing efficiencies and commercially competitive cost structure
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
